Stockscreener 앱 받기
28.61
2.03%
0.57
시간 외 거래:
28.61
전일 마감가:
$28.04
열려 있는:
$28.18
하루 거래량:
285.96K
Relative Volume:
0.80
시가총액:
$801.29M
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-13.31
EPS:
-2.15
순현금흐름:
$-19.25M
1주 성능:
+6.63%
1개월 성능:
-7.05%
6개월 성능:
+34.64%
1년 성능:
+37.61%
1일 변동 폭
$27.58
$29.07
1주일 범위
$25.82
$29.07
52주 변동 폭
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
28.61 | 801.29M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
532.02 | 203.50B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
234.84 | 169.62B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
135.69 | 38.75B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.39 | 35.83B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
415.53 | 34.03B | 3.84B | 866.24M | 792.60M | 10.37 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences (NASDAQ:CSTL) Given Overweight Rating at Stephens - Defense World
Castle Biosciences (NASDAQ:CSTL) Earns Overweight Rating from Stephens - MarketBeat
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock - Benzinga
Brokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - Defense World
Barclays PLC Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Geode Capital Management LLC Increases Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Analysts Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Holdings Lifted by Franklin Resources Inc. - MarketBeat
Castle Biosciences reports preliminary data from atopic dermatitis test study - Yahoo! Voices
State Street Corp Acquires 60,924 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences to launch AD test by end of 2025 - Investing.com Canada
Castle Biosciences Unveils Promising Early Data for Revolutionary Atopic Dermatitis Test - StockTitan
Principal Financial Group Inc. Buys 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $265,357 in shares - Investing.com India
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 9,364 Shares of Stock - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $265,357 in shares By Investing.com - Investing.com South Africa
The True Test of Success - BOSS Magazine
Castle Biosciences Awards Major RSU Package to 135 Employees in Strategic Retention Move - StockTitan
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade - MSN
Castle Biosciences CEO Derek Maetzold sells $750,296 in stock - Investing.com India
Short Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Expands By 7.6% - MarketBeat
Captrust Financial Advisors Decreases Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $160,741 in shares - Investing.com India
Castle Biosciences CEO Derek Maetzold sells $160,741 in shares By Investing.com - Investing.com UK
Point72 Asset Management L.P. Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences director Daniel Bradbury sells $243,692 in stock By Investing.com - Investing.com Canada
Castle Biosciences director Daniel Bradbury sells $243,692 in stock - Investing.com India
Jacobs Levy Equity Management Inc. Has $14.16 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences Inc (CSTL) Trading 3% Higher on Dec 4 - GuruFocus.com
Parkman Healthcare Partners LLC Purchases 18,176 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives $37.88 Consensus Target Price from Analysts - MarketBeat
Castle Biosciences Inc (CSTL) Stock Price Down 3.73% on Dec 2 - GuruFocus.com
Bellevue Group AG Buys 44,929 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Braidwell LP Sells 84,114 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Bought by Dynamic Technology Lab Private Ltd - MarketBeat
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
Castle Biosciences to Present at Piper Sandler Healthcare Conference in December | CSTL Stock News - StockTitan
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why - MSN
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Castle Biosciences Inc 주식 (CSTL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Dec 13 '24 |
Sale |
28.64 |
13,485 |
386,209 |
105,185 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Dec 16 '24 |
Sale |
28.83 |
11,059 |
318,864 |
94,126 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Dec 13 '24 |
Sale |
28.64 |
1,579 |
45,223 |
5,702 |
0.42%
자본화:
|
볼륨(24시간):